A338840 Stock Overview
An antibody new drug development platform company, engages in the research and development of immuno-oncology drugs and antibody drugs. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Y-Biologics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩8,140.00 |
| 52 Week High | ₩14,370.00 |
| 52 Week Low | ₩6,400.00 |
| Beta | 0 |
| 1 Month Change | 5.30% |
| 3 Month Change | -33.00% |
| 1 Year Change | -39.84% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -36.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| A338840 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 0.9% | 4.0% | 5.2% |
| 1Y | -39.8% | 13.2% | -4.3% |
Return vs Industry: A338840 underperformed the KR Biotechs industry which returned 13.2% over the past year.
Return vs Market: A338840 underperformed the KR Market which returned -4.3% over the past year.
Price Volatility
| A338840 volatility | |
|---|---|
| A338840 Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in KR Market | 12.8% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A338840 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A338840's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | n/a | Young Woo Park | www.ybiologics.com |
Y-Biologics, Inc., an antibody new drug development platform company, engages in the research and development of immuno-oncology drugs and antibody drugs. It develops YBL-006, a PD-1 immune checkpoint inhibitor that is in clinical phase 1/2a medication for solid cancers. The company also develops mono-specific antibodies, such as YBL-011 and YBL-003 for solid cancers; YBL-013, an ALiCE antibody for solid cancers; and YBL-001, an anti-drug conjugate for small cell lung and liver cancers.
Y-Biologics, Inc. Fundamentals Summary
| A338840 fundamental statistics | |
|---|---|
| Market cap | ₩121.85b |
| Earnings (TTM) | ₩0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A338840 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A338840 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩0 |
| Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A338840 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 12:16 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | N/A |
| Annual Earnings | N/A |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Y-Biologics, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|